Frontline therapy in mantle cell lymphoma: The role of high-dose therapy and integration of new agents

Current Hematologic Malignancy Reports

Volumn 4, Issue 4, 2009, Pages 213-217

  Kahl, Brad S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; BORTEZOMIB; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; IBRITUMOMAB TIUXETAN; LENALIDOMIDE; MELPHALAN; METHOTREXATE; PREDNISOLONE; PREDNISONE; RITUXIMAB; TEMSIROLIMUS; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; DRUG MEGADOSE; HEMATOLOGIC DISEASE; HUMAN; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGNOSIS; RADIOIMMUNOTHERAPY; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, MANTLE-CELL; NITROGEN MUSTARD COMPOUNDS; PYRAZINES; RADIOIMMUNOTHERAPY; SIROLIMUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 70349748583     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-009-0028-z     Document Type: Review

References (27)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997, 89: 3909-3918.
2. Herrmann A, Hoster E, Zwingers T, et al.: Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009, 27: 511-518.
3. Kienle D, Katzenberger T, Ott G, et al.: Quantitative gene expression deregulation in mantle-cell lymphoma: Correlation with clinical and biologic factors. J Clin Oncol 2007, 25: 2770-2777.
4. Jares P, Colomer D, Campo E: Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for new targeted therapeutics. Nat Rev Cancer 2007, 7: 750-762.
5. Martin P, Coleman M, Leonard JP: Progress in mantle-cell lymphoma. J Clin Oncol 2009, 27: 481-483.
6. Rosenwald A, Wright G, Wiestner A, et al.: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3: 185-197.
7. Hartmann E, Fernandez V, Moreno V, et al.: Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol 2008, 26: 4966-4972.
8. Determann O, Hoster E, Ott G, et al.: Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: Results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008, 111: 2385-2387.
9. Katzenberger T, Petzoldt C, Höller S, et al.: The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006, 107: 3407.
10. Hoster E, Dreyling M, Klapper W, et al.: A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008, 111: 558-565.
11. Lenz G, Dreyling M, Hoster E, et al.: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005, 23: 1984-1992.
12. Howard OM, Gribben JG, Neuberg DS, et al.: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002, 20: 1288-1294.
13. Romaguera JE, Fayad L, Rodriguez MA, et al.: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005, 23: 7013-7023.
14. Fayad L, Thomas DA, Romaguera J: Update of the M.D. Anderson Cancer Center experience with hyperCVAD and rituximab for the treatment of mantle cell and Burkitttype lymphomas. Clin Lymphoma Myeloma 2007, 8(Suppl 2): S57-S62.
15. Epner E, Unger JM, Miller TP, et al.: A multi center trial of hyperCVAD + Rituxan in patients with newly diagnosed mantle cell lymphoma [abstract 387]. Blood (ASH Annual Meeting Abstracts) 2007, 110: Abstract 387.
16. Dreyling M, Hoster E, van Hoof A, et al.: Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission of mantle cell lymphoma [abstract 769]. Blood (ASH Annual Meeting Abstracts) 2008, 112: 285.
17. Dreyling M, Lenz G, Hoster E, et al.: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 2005, 105: 2677-2684.
18. Geisler CH, Kolstad A, Laurell A, et al.: Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112: 2687-2693.
19. Delarue R, Haioun C, Ribrag V, et al.: RCHOP and RDHAP followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma: final results of a phase II study from the GELA [abstract 581]. Blood (ASH Annual Meeting Abstracts) 2008, 112: 218.
20. Fisher RI, Bernstein SH, Kahl BS, et al.: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006, 24: 4867-4874.
21. Kahl B, Chang J, Eickhoff J, et al.: VcR-CVAD produces a high complete response rate in untreated mantle cell lymphoma: A phase II study from the Wisconsin Oncology Network [abstract 265]. Blood (ASH Annual Meeting Abstracts) 2008, 112: 104.
22. Smith M, Zhang L, Gordon L, et al.: Phase II study of RCHOP followed by 90 Y-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group Study E1499 [abstract 389]. Blood (ASH Annual Meeting Abstracts) 2007, 110: Abstract 389.
23. Kahl B, Longo W, Eickhoff J, et al.: Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network. Ann Oncol 2006, 17: 1418-1423.
24. Hess G, Herbrecht R, Romaguera J, et al.: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27: 3822-3829.
25. Reeder C, Gornet M, Habermann T, et al.: A phase II trial of the oral mTOR inhibitor everolimus (RADOO1) in relapsed aggressive non-Hodgkin lymphoma [abstract 121]. Blood (ASH Annual Meeting Abstracts) 2007, 110: Abstract 121.
26. Zinzani PL, Witzig TE, Vose JM, et al.: Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle cell lymphoma: Results of an international study (NHL-003) [abstract 262]. Blood (ASH Annual Meeting Abstracts) 2008, 112: 104.
27. Rummel M, von Gruenhagen U, Niederle N, et al.: Bendamustine plus rituximab versus CHOP plus rituximab in the first line treatment of patients with follicular, indolent, and mantle cell lymphomas: Results of a randomized phase III study of the Study Group Indolent Lymphomas (StiL) [abstract 2596]. Blood (ASH Annual Meeting Abstracts) 2008, 112: 900.